| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA
|
Trump, Donald L
|
|
2003
|
21 |
5 |
p. 412-413
2 p.
|
artikel
|
| 2 |
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ, Mayo Clinic and Mayo Foundation, Rochester, MN
|
Trump, Donald L
|
|
2003
|
21 |
5 |
p. 409-410
2 p.
|
artikel
|
| 3 |
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group, Uro-Oncology Clinic, Centre Hospitalier de l’Université, de Montreal, Hôpital Notre-Dame, Montréal, Québec, Canada
|
Trump, Donald L
|
|
2003
|
21 |
5 |
p. 408-
1 p.
|
artikel
|
| 4 |
Bacillus calmete-guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity
|
Lam, John S.
|
|
2003
|
21 |
5 |
p. 354-360
7 p.
|
artikel
|
| 5 |
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group, Medical College of Wisconsin, Milwaukee, WI
|
Trump, Donald L
|
|
2003
|
21 |
5 |
p. 408-409
2 p.
|
artikel
|
| 6 |
Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Levine L, Lucci JA 3rd, Pazdrak B, Cheng JZ, Guo YS, Townsend CM Jr, Hellmich MR, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX 77555
|
Bosland, Maarten
|
|
2003
|
21 |
5 |
p. 415-
1 p.
|
artikel
|
| 7 |
Bone loss and the evolving role of bisphosphonate therapy in prostate cancer☆ ☆ This work was supported by research funding from Novartis Oncology.
|
Higano, Celestia S
|
|
2003
|
21 |
5 |
p. 392-398
7 p.
|
artikel
|
| 8 |
Brief summary
|
|
|
2003
|
21 |
5 |
p. ii-
1 p.
|
artikel
|
| 9 |
Chromosome 18 suppresses prostate cancer metastases
|
Padalecki, S.S.
|
|
2003
|
21 |
5 |
p. 366-373
8 p.
|
artikel
|
| 10 |
Commentary on the next two abstracts follows the second abstract. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
|
Trump, Donald L.
|
|
2003
|
21 |
5 |
p. 410-
1 p.
|
artikel
|
| 11 |
Correlation between p53 mutations and HPV in bilharzial bladder cancer
|
Khaled, Hussein M
|
|
2003
|
21 |
5 |
p. 334-341
8 p.
|
artikel
|
| 12 |
Development of weekly high-dose calcitriol based therapy for prostate cancer☆ ☆ Presented at the Third Annual SUO Meeting: Urologic Oncology: Extraordinary Opportunities for Discovery Meeting, co-sponsored by the NCI, Bethesda, MD, 13–14 December 2002.
|
Beer, Tomasz M
|
|
2003
|
21 |
5 |
p. 399-405
7 p.
|
artikel
|
| 13 |
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231
|
Bosland, Maarten
|
|
2003
|
21 |
5 |
p. 414-415
2 p.
|
artikel
|
| 14 |
Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Widmark A, Fossa SD, Lundmo P, Damber JE, Vaage S, Damber L, Wiklund F, Klepp O, Department of Oncology, Umea University, Umea, Sweden
|
Trump, Donald L
|
|
2003
|
21 |
5 |
p. 407-
1 p.
|
artikel
|
| 15 |
Editorial board
|
|
|
2003
|
21 |
5 |
p. iii-
1 p.
|
artikel
|
| 16 |
Editorial comment
|
Penson, David F.
|
|
2003
|
21 |
5 |
p. 353-
1 p.
|
artikel
|
| 17 |
Editorial comment
|
Schellhammer, Paul F.
|
|
2003
|
21 |
5 |
p. 353-
1 p.
|
artikel
|
| 18 |
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
|
Trump, Donald L
|
|
2003
|
21 |
5 |
p. 410-411
2 p.
|
artikel
|
| 19 |
Emerging technologies in uroradiologic imaging
|
Janzen, Nicolette K
|
|
2003
|
21 |
5 |
p. 317-326
10 p.
|
artikel
|
| 20 |
Erratum to survey section abstract ‘treatment outcome, body image, and sexual functioning after orchiectomy and radiotherapy for stage I–II testicular seminoma’
|
Incrocci, L.
|
|
2003
|
21 |
5 |
p. 418-
1 p.
|
artikel
|
| 21 |
Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Li M, Ittmann MM, Rowley DR, Knowlton AA, Vaid AK, Epner DE, Departments of Medicine, Pathology, Molceular and Cellular Biology, Baylor College of Medicine and VA Medical Center Houston, TX 77030
|
Bosland, Maarten
|
|
2003
|
21 |
5 |
p. 415-416
2 p.
|
artikel
|
| 22 |
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL, Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, and Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, LA
|
Trump, Donald L
|
|
2003
|
21 |
5 |
p. 411-412
2 p.
|
artikel
|
| 23 |
Histologic confirmation of lesions identified by Prostascint® scan following definitive treatment
|
Bermejo, Carlos E.
|
|
2003
|
21 |
5 |
p. 349-352
4 p.
|
artikel
|
| 24 |
Information for authors
|
|
|
2003
|
21 |
5 |
p. IBC-
1 p.
|
artikel
|
| 25 |
In vivo regulation of hTERT expression and telomerase activity by androgen. Guo C, Armbruster BN, Price DT, Counter CM, Department of Pharmacology, Duke University Medical Center, Durham, NC 27710
|
Bosland, Maarten
|
|
2003
|
21 |
5 |
p. 416-
1 p.
|
artikel
|
| 26 |
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M, Department of Medicine, University of Chicago, Chicago, IL
|
Trump, Donald L
|
|
2003
|
21 |
5 |
p. 413-
1 p.
|
artikel
|
| 27 |
Mark your calendar
|
|
|
2003
|
21 |
5 |
p. OBC-
1 p.
|
artikel
|
| 28 |
Masthead
|
|
|
2003
|
21 |
5 |
p. iv-
1 p.
|
artikel
|
| 29 |
Mayo clinic
|
|
|
2003
|
21 |
5 |
p. II-
1 p.
|
artikel
|
| 30 |
Osteoporosis and prostate cancer
|
Moyad, Mark A.
|
|
2003
|
21 |
5 |
p. 374-
1 p.
|
artikel
|
| 31 |
Osteoporosis: a rapid review of risk factors and screening methods
|
Moyad, Mark A
|
|
2003
|
21 |
5 |
p. 375-379
5 p.
|
artikel
|
| 32 |
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
|
Trump, Donald L
|
|
2003
|
21 |
5 |
p. 412-
1 p.
|
artikel
|
| 33 |
Prostatic androgen repressed message-1 (PARM-1) may play a role in prostatic cell immortalisation. Cornet AM, Hanon E, Reiter ER, Bruyninx M, Nguyen VH, Hennuy BR, Hennen GP, Closset JL, Biochemistry and Laboratory of Endocrinology, Institute of Pathology B23, Avenue de l’Hopital 3, University of Liege, 4000 Liege, Belgium
|
Bosland, Maarten
|
|
2003
|
21 |
5 |
p. 417-
1 p.
|
artikel
|
| 34 |
Risk factors for male osteoporosis
|
Conde, Francisco A
|
|
2003
|
21 |
5 |
p. 380-383
4 p.
|
artikel
|
| 35 |
Seminar in this issue
|
|
|
2003
|
21 |
5 |
p. IFC-
1 p.
|
artikel
|
| 36 |
Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi
|
Sweeney, Paul
|
|
2003
|
21 |
5 |
p. 327-333
7 p.
|
artikel
|
| 37 |
Survey section
|
|
|
2003
|
21 |
5 |
p. 406-
1 p.
|
artikel
|
| 38 |
Table of contents
|
|
|
2003
|
21 |
5 |
p. v-vi
nvt p.
|
artikel
|
| 39 |
The potential benefits of dietary and/or supplemental calcium and vitamin D
|
Moyad, Mark A
|
|
2003
|
21 |
5 |
p. 384-391
8 p.
|
artikel
|
| 40 |
The utility of apical anterior horn biopsies in prostate cancer detection
|
Meng, Maxwell V.
|
|
2003
|
21 |
5 |
p. 361-365
5 p.
|
artikel
|
| 41 |
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, α-interferon, cisplatin (FAP)
|
Tu, Shi-Ming
|
|
2003
|
21 |
5 |
p. 342-348
7 p.
|
artikel
|
| 42 |
When you see advanced prostate cancer
|
|
|
2003
|
21 |
5 |
p. i-
1 p.
|
artikel
|
|
Tijdschrift beschrijving